Xilio TherapeuticsXLO
13F holders, Q1 2026 (March 31)1holders −36
0new positions
19sold out
$8.41avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding Xilio Therapeutics Inc. (XLO) in their 13F filings, down 36 from Q4 2025. 0 opened new positions and 19 sold out. The largest holder was Gilead Sciences, Inc. ($5.5M).
- Company
- Xilio Therapeutics Inc.
- CUSIP
- 98422T100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 19 | $5.1M |
All 13F filers, Q4 2025 → Q1 2026: 16,477,981 shares sold, net −16,477,981 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Gilead Sciences, Inc. | 0.26% | Reduce -92.9% | 650,389 | $5.5M |
"% of holder's portfolio" is XLO's weight in each manager's 13F, not the share of Xilio Therapeutics Inc. the manager owns.